What are the common adverse effects of zanubrutinib and how should they be monitored and managed?

Zanubrutinib Side Effects

Zanubrutinib demonstrates a favorable safety profile compared to first-generation BTK inhibitors, with significantly lower rates of atrial fibrillation (4% vs 17% with ibrutinib) but higher rates of neutropenia (29% any grade, 20% grade ≥3) requiring proactive monitoring and management. 1

Hematologic Adverse Effects

Neutropenia is the most significant hematologic concern with zanubrutinib:

• Any grade neutropenia occurs in 29% of patients (compared to 13% with ibrutinib)
• Grade ≥3 neutropenia occurs in 20% of patients (compared to 8% with ibrutinib)
• A larger proportion of patients require granulocyte colony-stimulating factor support 1

Other hematologic toxicities include:

• Thrombocytopenia: 8% grade ≥3 2
• Anemia: 8% grade ≥3 2

Monitor complete blood counts regularly, particularly during the first 6 months of therapy. Consider G-CSF support for grade ≥3 neutropenia, especially if associated with infections.

Cardiovascular Adverse Effects

Zanubrutinib shows markedly improved cardiac safety compared to ibrutinib:

Atrial Fibrillation:

• Occurs in only 4% of zanubrutinib patients versus 17% with ibrutinib 1
• This represents a 4-fold reduction in risk, a critical advantage for elderly patients with cardiac comorbidities
• Grade ≥3 atrial fibrillation is rare (1-2%) 3

Hypertension:

• Occurs in 4-5% of patients 1
• Grade ≥3 hypertension in approximately 2-3% 3
• Manage with standard antihypertensive therapy; discontinuation rarely required

Bleeding:

• Major hemorrhage occurs in 4% of patients 2
• Any grade bleeding in 26-39% 2
• Grade ≥3 bleeding in only 2% 3

Monitor blood pressure at each visit. Screen for atrial fibrillation with ECG at baseline and if patients develop palpitations, dizziness, or dyspnea. Consider non-warfarin anticoagulation if atrial fibrillation develops, as warfarin is contraindicated with zanubrutinib. 4

Infectious Complications

Upper respiratory tract infections are the most common infectious adverse event:

• URI occurs in 39% of patients 2
• Pneumonia in 21% (11% grade ≥3) 2
• Urinary tract infections in 15% 2
• Sepsis in 2% 2

Fatal infectious complications occurred in 4% of patients in pooled analyses, with pneumonia (n=9) and sepsis (n=4) being the most common causes 2.

Prophylactic strategies should be individualized based on infection history. Universal antiviral prophylaxis against HSV/VZV is not recommended but should be considered in patients with recurrent reactivations or those receiving concomitant high-dose steroids or rituximab. 5

Common Non-Hematologic Adverse Effects

The most frequent non-hematologic adverse events include:

• Rash: 27% 2
• Bruising: 25% 2
• Musculoskeletal pain: 24% 2
• Diarrhea: 23% (2% grade ≥3) 2
• Cough: 21% 2
• Fatigue: 15% 2

Most of these are grade 1-2 and manageable with supportive care. Grade ≥3 non-hematologic events are uncommon (2% for most categories) 2.

Treatment Discontinuation and Tolerability

Zanubrutinib demonstrates excellent long-term tolerability:

• Treatment discontinuation due to adverse events: 10% 2
• Dose reductions required: 8% 2
• Median treatment duration: 26 months (range 0.1-65 months) 2
• 16% of patients treated for ≥3 years 2

This compares favorably to ibrutinib, where approximately 20% of patients discontinue due to toxicity.

Critical Drug Interactions

CYP3A Inhibitors:

• Moderate/strong CYP3A inhibitors increase zanubrutinib exposure and toxicity risk
• Reduce zanubrutinib dose when coadministered with these agents 4

CYP3A Inducers:

• Moderate/strong CYP3A inducers decrease zanubrutinib efficacy
• Avoid coadministration with strong inducers
• If moderate inducers cannot be avoided, increase zanubrutinib to 320 mg twice daily 4

Anticoagulation:

• Warfarin is contraindicated with zanubrutinib
• Use non-warfarin anticoagulants (DOACs preferred) if anticoagulation is required
• Monitor closely for bleeding with any anticoagulant 4

Special Populations

Elderly patients (≥65 years):

• Represent 59% of treated patients in clinical trials
• Higher rates of grade ≥3 adverse events (57% vs 51% in younger patients)
• Higher rates of serious adverse events (38% vs 29%) 4
• No dose adjustment required, but closer monitoring warranted

Renal impairment:

• No dose modification needed for mild, moderate, or severe impairment (CrCl ≥15 mL/min)
• Monitor closely in dialysis patients 4

Hepatic impairment:

• No dose adjustment for mild-moderate impairment
• Reduce dose in severe hepatic impairment 4

Pregnancy and Reproductive Considerations

• Category D equivalent: Can cause fetal harm based on animal data showing cardiac malformations at 5-fold human exposure 4
• Pregnancy testing required before initiating therapy
• Effective contraception mandatory during treatment and for 1 week after last dose
• Avoid breastfeeding during treatment and for 2 weeks after last dose 4

Comparative Safety Advantage

The ASPEN trial directly compared zanubrutinib to ibrutinib, demonstrating:

• Lower atrial fibrillation: 4% vs 17% (P<0.05) 1
• Lower overall cardiac events 3
• Fewer treatment discontinuations due to adverse events 3
• Lower rates of most non-hematologic adverse events 1

The only exception is neutropenia, which occurs at 2-fold higher rates with zanubrutinib, though this is generally manageable with G-CSF support 1.